Ezetimibe/Simvastatin

依折麦布/辛伐他汀

Report date: 2024/02/21 13:45:24

Base Information

Drug NameEzetimibe/Simvastatin
Drug Alias NameSimvastatin/Ezetimibe辛伐他汀/依折麦布依折麦布辛伐他汀Ezetimibe and SimvastatinSimvastatin and Ezetimibe +[9] 
ClassificationSmall molecules
Mechanisms of ActionHMG-CoA reductase inhibitorsNiemann-Pick C1-like protein 1 inhibitorsCholesterol absorption inhibitors
TargetsHMG-CoA reductaseNiemann-Pick C1-like protein 1
Therapy Area/IndicationsHypercholesterolemiaHyperlipidemiasAlopecia Areata +[9] 
Global Approved IndicationsHyperlipidemiasHyperlipoproteinemia Type IIHyperlipidemia, Familial Combined +[5] 
Approved Indications in ChinaHyperlipidemiasHyperlipoproteinemia Type IIHyperlipidemia, Familial Combined +[5] 
Original Approved Country/TerritoryUnited States
Original Approved Date2004/07/23
Country/TerritoryUnited StatesMainland China
CombinationsYes EzetimibeSimvastatin
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMerck & Co Inc
China Registration ClassN/A

Develop Information

Active CompaniesOrganonMsp Singapore Company Llc
Inactive CompaniesUniversity Of MiamiMerck Sharp & Dohme LLCOrganon & Co
Active IndicationsHyperlipidemiasHyperlipoproteinemia Type IIHyperlipidemia, Familial Combined +[5] 
Inactive IndicationsHypercholesterolemiaAlopecia AreataAtherosclerosis +[4] 

Other Information

ATC CodeC10BA02
Related LinksWikipediaKEGG